Executive Management: served as a "crucial key member" and de facto PI, managing laboratory operations, budget control, and international collaborations. Scientific Breakthroughs: directed research proving that translational errors drive premature aging and Alzheimer-like pathology in mice, published in Science Advances and Cell Reports. Drug Discovery: co-led the development of next-generation aminoglycoside antibiotics, achieving superior selectivity and reduced toxicity through SAR-based design.

Spearheaded projects monitoring translation fidelity in vivo over lifetimes, identifying systemic drivers of age-related disease.

Conceptualized and launched a "quality control" therapeutic approach to treat Alzheimer’s and Parkinson’s by enhancing ribosomal accuracy.